MaaT013 – A Dysbiosis Correcting Live Biotherapeutic for the Treatment of Acute Graft-vs-host-Disease

Time: 1:45 pm
day: Day 2 - Track B Evening


  • Introduction to MaaT Pharma’s Microbiome Ecosystem Therapies platform
  • Discussion of recent results obtained in 76 patients with acute Graft-versus-Host Disease with MaaT013
  • Perspectives for microbiome ecosystem-based therapeutic approaches